COMMUNIQUÉS West-GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
20/02/2026
SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
20/02/2026
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb [...]
Vistin Pharma ASA: Mandatory notification of trade
20/02/2026
Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following [...]
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
20/02/2026
VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
20/02/2026
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help address a significant [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
20/02/2026
Company Announcement COPENHAGEN, Denmark; February 20, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 janvier 2026
20/02/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting
20/02/2026
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present Phase 1/2 [...]
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
20/02/2026
WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve ® Antimicrobial wound gel in the International Wound [...]
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
20/02/2026
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
ABLi Therapeutics Announces Publication of the Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease
20/02/2026
The trial data, published today in Nature Aging, highlights the safety, tolerability and preliminary measures of potential clinical benefit and reports the first treatment-dependent reduction in alpha-synuclein [...]
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
20/02/2026
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
20/02/2026
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or [...]
AltruBio Announces Formation of Inflammatory Bowel Disease Clinical Advisory Board
20/02/2026
World-renowned medical experts with extensive experience in treating patients with inflammatory bowel disease join AltruBio to support clinical advancement of ALTB-268 for the treatment of ulcerative colitis SAN [...]
Nasus Pharma to Participate in Upcoming Investor Conferences
20/02/2026
TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today [...]
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
20/02/2026
– Administration of PEDMARK ® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation [...]
VitalHub Announces Q4 2025 Conference Call Date
20/02/2026
TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") is pleased to announce that it will release financial results for the fourth quarter 2025 ended December 31 [...]
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
20/02/2026
POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived [...]
Lifeward Announces Reverse Share Split
20/02/2026
Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: [...]

Pages